BR0112721A - Uso de fosfato de estramustina no tratamento de metastase óssea - Google Patents

Uso de fosfato de estramustina no tratamento de metastase óssea

Info

Publication number
BR0112721A
BR0112721A BR0112721-7A BR0112721A BR0112721A BR 0112721 A BR0112721 A BR 0112721A BR 0112721 A BR0112721 A BR 0112721A BR 0112721 A BR0112721 A BR 0112721A
Authority
BR
Brazil
Prior art keywords
treatment
estramustine phosphate
bone metastasis
bone
phosphate
Prior art date
Application number
BR0112721-7A
Other languages
English (en)
Inventor
Beryl Asp
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0112721A publication Critical patent/BR0112721A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

"USO DE FOSFATO DE ESTRAMUSTINA NO TRATAMENTO DE METASTASE óSSEA". O fosfato de estramustina é mostrado para agir como um inibidor de reabsorção óssea e pode ser usado assim, para tratar, prevenir ou aliviar os sintomas de metástase óssea que surgem devido a dita reabsorção óssea.
BR0112721-7A 2000-07-25 2001-07-23 Uso de fosfato de estramustina no tratamento de metastase óssea BR0112721A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,540 US6436913B1 (en) 2000-07-25 2000-07-25 Use of estramustine phosphate in the treatment of bone metastasis
PCT/US2001/023179 WO2002007719A1 (en) 2000-07-25 2001-07-23 Use of estramustine phosphate in the treatment of bone metastasis

Publications (1)

Publication Number Publication Date
BR0112721A true BR0112721A (pt) 2003-06-24

Family

ID=24506563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112721-7A BR0112721A (pt) 2000-07-25 2001-07-23 Uso de fosfato de estramustina no tratamento de metastase óssea

Country Status (13)

Country Link
US (1) US6436913B1 (pt)
EP (1) EP1328264A4 (pt)
JP (1) JP2004504346A (pt)
KR (1) KR20030019612A (pt)
CN (1) CN1446086A (pt)
AR (1) AR029958A1 (pt)
AU (1) AU2001277115A1 (pt)
BR (1) BR0112721A (pt)
CA (1) CA2412392A1 (pt)
MX (1) MXPA03000313A (pt)
PE (1) PE20020301A1 (pt)
WO (1) WO2002007719A1 (pt)
ZA (1) ZA200210285B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
US20040014729A1 (en) * 2001-07-23 2004-01-22 Beryl Asp Use of estramustine phosphate in the treatment of bone metastasis
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
JP2005055881A (ja) * 2003-07-22 2005-03-03 Fuji Photo Film Co Ltd 描画方法および描画装置
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
BR9906425A (pt) * 1998-03-27 2000-07-11 Upjohn Co Métodos para potencializar fosfato de estramustina intravenoso
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death

Also Published As

Publication number Publication date
CA2412392A1 (en) 2002-01-31
KR20030019612A (ko) 2003-03-06
EP1328264A4 (en) 2004-01-28
AR029958A1 (es) 2003-07-23
EP1328264A1 (en) 2003-07-23
ZA200210285B (en) 2003-12-19
PE20020301A1 (es) 2002-04-07
JP2004504346A (ja) 2004-02-12
WO2002007719A1 (en) 2002-01-31
AU2001277115A1 (en) 2002-02-05
US6436913B1 (en) 2002-08-20
CN1446086A (zh) 2003-10-01
MXPA03000313A (es) 2003-06-06

Similar Documents

Publication Publication Date Title
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
BR9708632A (pt) Composto calcilìticos
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
BR0014041A (pt) Utilização de csaids em infecção por rinovìrus
BRPI0407950A (pt) processo para a preparação de uma composição de higiene pessoal
ES2176605T3 (es) Sutura quirurgica.
BR0307522A (pt) Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
BR0210013A (pt) Gel oftálmico de pirenzepina
AR035987A1 (es) Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
BR0113644A (pt) Usos do inibidor de pde5 no tratamento de enxaqueca
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
BR0112721A (pt) Uso de fosfato de estramustina no tratamento de metastase óssea
BR0112547A (pt) Processo para encontrar compostos que sejam adequados para o tratamento e/ou profilaxia de obesidade
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
PE20001505A1 (es) Metodo para tratar epoc
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2021 DE 29/09/2009.